For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 2,585 | 2,891 | ||
| Selling, general and administrative expenses | 2,298 | 4,158 | ||
| Loss from operations | -4,883 | -7,049 | ||
| Realized gains from sales of trading securities | 208 | 239 | ||
| Unrealized gain (loss) from trading securities | -39 | -79 | ||
| Interest income, net | 175 | 195 | ||
| Total other income | 344 | 355 | ||
| Net loss | -4,539 | -6,694 | ||
| Basic EPS | -0.23 | -0.33 | ||
| Diluted EPS | -0.23 | -0.33 | ||
| Basic Average Shares | 20,155,000 | 20,352,000 | ||
| Diluted Average Shares | 20,155,000 | 20,352,000 | ||
enVVeno Medical Corp (NVNBW)
enVVeno Medical Corp (NVNBW)